Sulfonylureas and cardiovascular complications of type 2 diabetes mellitus
https://doi.org/10.14341/2072-0351-3753
Abstract
This article addresses possible mechanisms for development of cardiovascular events (CVE) in type 2 diabetes mellitus (T2DM) patients treated with sulfonylurea derivatives (SU). Several problems are highlighted in this review, including molecular aspects of pancreatic and extrapancreatic action of these drugs, their comparative potential to induce hypoglycemic events (as predictors of acute CVE) and impairment of ischemic preconditioning, as well as antiarrhythmic activity of certain SU agents. Finally, efficacy and cardiovascular safety of glimepiride in T2DM patients is substantiated based on a survey of current literature.
About the Author
Lyudmila Viktorovna Nedosugova
I.M. Sechenov First Moscow State Medical University, Moscow
d.m.n., prof. kafedry endokrinologii fakul'teta poslevuzovskogo professional'nogo obrazovaniya vrachey
References
1. World Health Organisation: ”The World Health Report 1998. Life in 21st Century – a Vision for ALL” Geneva: World Health Organisation; 1998.
2. Cунцов Ю.И. Современные сахароснижающие препараты, используемые в России при лечении сахарного диабета типа. Сахарный диабет. 2012;(1):6–10.
3. Hsueh WA, Law RE. Cardiovascular risk continuum: Implications of insulin resistance and diabetes. Am J Med. 1998 Jul 6;105(1A):4S–14S.
4. O'Brien RC, Luo M. The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro. Metabolism. 1997 Dec;46(12 Suppl 1):22–25.
5. Доборджгинидзе Л.М., Грацианский Н.А. Роль статинов в коррекции диабетической дислипидемии. Сахарный диабет. 2001; (2): 41–47.
6. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999 Feb;22(2):233–240.
7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837–853.
8. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulintherapy prevents the progression of diabetic microvascular complications in Japanese patients with NIDDM: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995 May;28(2):103–117.
9. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poul- ter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2560–2572. doi: http://dx.doi.org/10.1056/NEJMoa0802987
10. Gaede P, Valentine WJ, Palmer AJ, Tucker DM, Lammert M, Parving HH, Pedersen O. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care. 2008 Aug;31(8):1510–1515. doi: http://dx.doi.org/10.2337/dc07-2452
11. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970;19:Suppl:789–830.
12. Seltzer HS. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes. 1972 Sep;21(9):976–979.
13. Feinglos MN, Bethel MA. Therapy of type 2 diabetes, cardiovascular death, and the UGDP. Am Heart J. 1999 Nov;138(5 Pt 1):S346–352.
14. Soler NG, Bennett MA, Pentecost BL, Fitzgerald MG, Malins JM. Myocardial infarction in diabetics. Q J Med. 1975 Jan;44(173):125–132.
15. Kereiakes DJ. Myocardial infarction in the diabetic patient. Clin Cardiol. 1985 Aug;8(8):446–450.
16. Soler NG, Pentecost BL, Bennett MA, FitzGerald MG, Lamb P, Malins JM. Coronary care for myocardial infarction. Lancet. 1974 Mar 23;1(7856):475–477.
17. Yudkin JS, Oswald GA. Determinants of hospital admission and case fatality in diabetic patients with myocardial infarction. Diabetes Care. 1988 Apr;11(4):351–358.
18. Króleski AS, Czyzyk A, Janeczko D, Kopczyński J. The fates of diabetic patients—Warsaw epidemiological study II. Mor- tality from coronary heart disease among diabetics in rela- tion to methods of hypoglycemic treatment. Acta Med Pol. 1977;18(3):213–230.
19. Richter B, Berger M. Randomized controlled trials remain fundamental to clinical decision making in Type II diabetes mellitus: A comment to the debate on randomized controlled trials. Diabetologia. 2000 Feb;43(2):254–258.
20. Connaughton M, Webber J. Diabetes and coronary artery disease: Time to stop taking the tablets? Heart. 1998 Aug;80(2):108–109.
21. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycaemia in type diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012 Jun;55(6):1577–1596. doi: http://dx.doi.org/10.1007/s00125-012-2534-0
22. International Diabetes Federation treatment algorithm for people with type 2 diabetes. Available from: http://www.idf.org/ Global_guideline. Accessed on March 29, 2012.
23. Ashcroft FM, Gribble FM. ATP-sensitivi K+channels and insulin secretion: their role in health and disease. Diabetologia. 1999 Aug;42(8):903–919.
24. Kitsios K, Tsapas A, Karagianni P. Glycemia and cardiovascular risk: challenging evidence based medicine Hippokratia. 2011 Jul;15(3):199–204.
25. Fisman EZ, Motro M, Tenenbaum A, Leor J, Boyko V, Mandelzweig L, Sherer Y, Adler Y, Behar S. Is hypoglycaemia a marker for increased long term mortality risk in patients with coronary artery disease? An 8-year follow-up. Eur J Cardiovasc Prev Rehabil. 2004 Apr;11(2):135–143.
26. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2545–2559. doi: http://dx.doi.org/10.1056/NEJMoa0802743
27. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 Jan 8;360(2):129–139. doi: http://dx.doi.org/10.1056/NEJMoa0808431
28. Müller G. The molecular mechanism of the insulin-mimetic/ sensitizing activity of the antidiabetic sulfonylurea drug amaryl. Mol Med. 2000 Nov;6(11):907–933.
29. Holsteinm A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev. 2001 Nov–Dec;17(6):467–473.
30. Lebovitz HE. Oral hypoglycemic agents. In: Rifkin H, Porte D. (eds.) Ellenberg and Rifkin’s Diabetes mellitus. Theory and Practise. New York: Elsevier; 1990. p. 554–574.
31. Müller G, Wied S, Wetekam EM, Crecelius A, Unkelbach A, Pünter J. Stimulation of glucose utilization in 3T3 adipocytes and rat diaphragm in vitro by the sulfonylureas, glimepiride and glibenclamide, is correlated with modulations of the cAMP regulatory cascade. Biochem Pharmacol. 1994 Aug 30;48(5):985–996.
32. Davidson MB, Molnar G, Furman A, Yamaguchi D. Glyburide- stimulated glucose transport in cultured muscle cells via protein kinase C-mediated pathway requiring new protein synthesis. Diabetes. 1991 Nov;40(11):1531–1538.
33. Rogers BJ, Standaert ML, Pollet RJ. Direct effects of sulfonylurea agents on glucose transport BC3H-1 myocyte. Diabetes. 1987 Nov;36(11):1292–1296.
34. Bak JF, Schmitz O, Sorensen NS, Pedersen O. Post-receptor effects of sulfonylurea on skeletal muscle glycogen synthase activity in type II diabetic patients. Diabetes. 1989 Nov;38(11):1343–1350.
35. Pulido N, Casla A, Suarez A, Casanova B, Arrieta FJ, Rovira A. Sulphonylurea stimulates glucose uptake in rats through an ATPsensitive K+ channel dependent mechanism. Diabetologia. 1996 Jan;39(1):22–27.
36. Nystrom FH, Quon MJ. Insulin signalling:Metabolic pathways and mechanismsfor specificity. Cell Signal. 1999 Aug;11(8):563–574.
37. Takada Y, Takata Y, Iwanishi M, Imamura T, Sawa T, Morioka H, Ishihara H, Ishiki M, Usui I, Temaru R, Urakaze M, Satoh Y, Inami T, Tsuda S, Kobayashi M. Effect of glimepiride (HOE490) on insulin receptors of skeletal muscles from genetically diabetic KK-Ay mouse. Eur J Pharmacol. 1996 Jul 18;308(2):205–210.
38. Terzic A, Jahangir A, Kurachi Y. Cardiac ATP-sensitive K1 channels: regulation by intracellular nucleotides and potassium opening drugs. Am J Physiol. 1995 Sep;269(3 Pt 1):C525–545.
39. Noma A. ATP-regulated K1 channel in cardiac muscle. Nature. 1983 Sep 8–14;305(5930):147–148.
40. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986 Nov;74(5):1124–1136.
41. Suzuki M, Sasaki N, Miki T, Sakamoto N, Ohmoto-Sekine Y, Tamagawa M, Seino S, Marbán E, Nakaya H. Role of sarcolemmal K(ATP) channels in cardioprotection against ischemia/reperfusion injury in mice. J Clin Invest. 2002 Feb;109(4):509–516.
42. Tomai F, Danesi A, Ghini AS, Crea F, Perino M, Gaspardone A, Ruggeri G, Chiariello L, Gioffrè PA. Effects of KATP channel blokade by glybenclamide on warm-up phenomenon. Eur Heart J. 1999 Feb;20(3):196–202.
43. Ashcroft FM, Gribble FM. ATP-sensitivi K+channels and insulin secretion: their role in health and disease. Diabetologia. 1999 Aug;42(8):903–919.
44. Olsson J, Lindberg G, Gottsäter M, Lindwall K, Sjöstrand A, Tisell A, Melander A. Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia. 2000 May;43(5):558–560.
45. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002 Dec;25(12):2244–2248.
46. Horsdal HT, Johnsen SP, Søndergaard F, Jacobsen J, Thomsen RW, Schmitz O, Sørensen HT, Rungby J. Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study. Diabetes Metab Res Rev. 2009 Sep;25(6):515–522. doi: http://dx.doi.org/10.1002/dmrr.971
47. Monami M, Luzzi C, Lamanna C, Chiasserini V, Addante F, Desideri CM, Masotti G, Marchionni N, Mannucci E. Three–year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev. 2006 Nov–Dec;22(6):477–482.
48. Ye Y, Perez-Polo JR, Aguilar D, Birnbaum Y. The potential ef- fects of anti-diabetic medications on myocardial ischemia-reper- fusion injury. Basic Res Cardiol. 2011 Nov;106(6):925–952. doi: http://dx.doi.org/10.1007/s00395-011-0216-6
49. Klepzig H, Kober G, Matter C, Luus H, Schneider H, Boedeker KH, Kiowski W, Amann FW, Gruber D, Harris S, Burger W. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J. 1999 Mar;20(6):439–446.
50. Mocanu MM, Maddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DM. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation. 2001 Jun 26;103(25):3111–3116.
51. Geisen K, Vegh A, Krause E, Papp JG. Cardiovascular effects of conventional sulfonylureas and glimepiride. Horm Metab Res. 1996 Sep;28(9):496–507.
52. Tanno M, Miura T, Tsuchida A, Miki T, Nishino Y, Ohnuma Y, Shimamoto K. Contribution of both the sarcolemmal KATP and mitochondrial KATP channels to infarct size limitation by KATP channel openers: differences from preconditioning in the role of sarcolemmal KATP channels. Naunyn Schmiedebergs Arch Pharmacol. 2001 Sep;364(3):226–232.
53. Rubart M, Zipes DP. Mechanism of sudden cardiac death. J Clin Invest. 2005 Sep;115(9):2305–2315.
54. Billman GE. The cardiac sarcolemmal ATP-sensitive potassium channel as a novel target for anti-arrhythmic therapy. Pharmacol Ther. 2008 Oct;120(1):54–70. doi: http://dx.doi.org/10.1016/j.pharmthera.2008.07.004
55. Sato T, Marbán E. The role of mitochondrial KATP channels in cardioprotection. Basic Res Cardiol. 2000 Aug;95(4):285–289.
56. Fischbach PS, White A, Barrett TD, Lucchesi BR. Risk of ventricu- lar proarrhythmia with selective opening of the myocardial sar- colemmal versus mitochondrial ATP-gated potassium channel. J Pharmacol Exp Ther. 2004 May;309(2):554–559.
57. Tweedie D, Henderson C, Kane K. Glibenclamide, but not class III drugs, prevents ischaemic shortening of the refrac- tory period in guinea-pig hearts. Eur J Pharmacol. 1993 Aug 24;240(2–3):251–257.
58. Davis TM, Parsons RW, Broadhurst RJ, Hobbs MS, Jamrozik K. Arrhythmias and mortality after myocardial infarction in diabetic patients. Relationship to diabetes treatment. Diabetes Care. 1998 Apr;21(4):637–640.
59. El-Reyani NE, Bozdogan O, Baczkó I, Leprán I, Papp JG. Comparison of the efficacy of glibenclamide and glimepiride in reperfusion-induced arrhythmias in rats. Eur J Pharmacol. 1999 Jan 22;365(2–3):187–192.
60. Arruda-Olson AM, Patch RK 3rd, Leibson CL, Vella A, Frye RL, Weston SA, Killian JM, Roger VL. Effect of Second-Generation Sulfonylureas on Survival in Patients With Diabetes Mellitus After Myocardial Infarction. Mayo Clin Proc. 2009;84(1):28–33. doi: http://dx.doi.org/10.1016/S0025-6196(11)60804-5
61. Zeller M, Danchin N, Simon D, Vahanian A, Lorgis L, Cottin Y, Berland J, Gueret P, Wyart P, Deturck R, Tabone X, Machecourt J, Leclercq F, Drouet E, Mulak G, Bataille V, Cambou JP, Ferrieres J, Simon T; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction investigators. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab. 2010 Nov;95(11):4993–5002. doi: http://dx.doi.org/10.1210/jc.2010-0449
Review
For citations:
Nedosugova L.V. Sulfonylureas and cardiovascular complications of type 2 diabetes mellitus. Diabetes mellitus. 2013;16(2):26-35. (In Russ.) https://doi.org/10.14341/2072-0351-3753
Views:
1504
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
